Inavolisib (Itovebi) is a new targeted therapy for HR+ HER2-negative metastatic breast cancer with a PIK3CA mutation.

The official results of the BRACELET-01 (PrECOG 0113) trial have been published in Clinical Cancer Research, detailing the ...

Erika Hamilton, MD, shares key insights from the 2025 ASCO Annual Meeting that are set to impact breast cancer treatment.

Omitting carboplatin from neoadjuvant treatment can improve safety without compromising efficacy in patients with HER2-positive early breast cancer.

Researchers evaluated current treatment patterns and clinical outcomes for patients with HER2-positive metastatic breast cancer.

A prognostic index can be used to identify patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer who can safely forgo adjuvant chemotherapy as well as p ...

Adding dalpiciclib to adjuvant endocrine therapy can improve outcomes in patients with HR-positive, HER2-negative early breast cancer.

Trastuzumab deruxtecan with pertuzumab significantly extended progression-free survival in HER2-positive advanced breast cancer, compared to standard THP therapy, according to DESTINY-Breast09 trial ...